NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01724801,Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer,https://clinicaltrials.gov/study/NCT01724801,BRAIN,COMPLETED,EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with EGFR-mutant non-small cell lung cancer.,NO,Brain Metastasis|Non Small Cell Lung Cancer,RADIATION: whole brain radiation(WBI)|DRUG: Icotinib,"iPFS, intracranial progression-free survival, 18 months","progress-free survival (PFS), progress-free survival, up to 16 months|time of controlling brain metastasis symptom, time of controlling brain metastasis symptom, 18months|Response rate of brain metastasis, Response rate of brain metastasis, 12months|Cognitive function, Cognitive function, 18months|overall survival(OS), overall survival(OS), 24months","Toxicity, adverse events(according to CTC4.0), 24months",Guangdong Association of Clinical Trials,Guangdong Provincial People's Hospital,ALL,"ADULT, OLDER_ADULT",PHASE3,176,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CTONG1201,2012-10-14,2015-06-30,2016-09-14,2012-11-12,,2017-03-01,"Guangdong General Hospital, Guangzhou, Guangdong, 510080, China|Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, China",
